Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| KL1010PL | Other Identifier | Company Internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
One of the most common adverse effects resulting from the therapy with thiazides, thiazide-like diuretics and loop diuretics is increased potassium secretion. Disregulation of plasma potassium may be a life-threatening condition due to increased risk of arrythmias. Moreover, it has been postulated that decrease in plasma potassium level may negatively affect glucose metabolism resulting in the increased risk of new-onset type 2 diabetes.The main goal of this study is to assess the efficacy and safety of telmisartan/hydrochlorothiazide in a broad population of hypertensive patients, including the effects of the therapy on plasma potassium level and also on selected parameters of glucose and lipid metabolism.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103) | Drug | Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment |
| Measure | Description | Time Frame |
|---|---|---|
| Change in systolic (SBP) and diastolic (DBP) blood pressure between first and final visit | approx. 3 mths after telmisartan/hydrochlorothiazide treatment initiation |
| Measure | Description | Time Frame |
|---|---|---|
| Change in plasma potassium between initial and final visit | approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation | |
| Change in fasting plasma glucose between initial and final visit | approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Primary care clinic hypertensive patients not treated with telmisartan/hydrochlorothiazide for approx. 3 mths.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many Locations | Poland |
Not provided
| ID | Term |
|---|---|
| D000075222 | Essential Hypertension |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077333 | Telmisartan |
| D006852 | Hydrochlorothiazide |
| ID | Term |
|---|---|
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
| Change in glycated haemoglobin A1C between initial and final visit | approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation |
| Change in plasma high density lipoprotein between initial and (continued) | approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation |
| Change in plasma low density lipoprotein between initial and final visit | approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation |
| Change in plasma cholesterol between initial and final visit | approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation |
| Change in plasma triglycerides between initial and final visit | approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation |
| Adverse events collection | approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D002740 | Chlorothiazide |
| D001581 | Benzothiadiazines |
| D013449 | Sulfonamides |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D049971 | Thiazides |